Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery
Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery to Reduce Intraoperative and Postoperative Blood Loss: A Randomized Clinical Trial.
Sponsor: Assiut University
Listed as NCT03148574, this PHASE3 trial focuses on Post Partum Hemorrhage and remains completed. Sponsored by Assiut University, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jan 2021 — May 2021 [monthly]
Unknown Status PHASE3
▶ Show 5 earlier versions
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jul 2018 — Jul 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assiut University
For direct contact, visit the study record on ClinicalTrials.gov .